- Raised $30M funding round, Feb 2017
- Raised $12M funding round led by Kreos Capital, Jul 2021
- Raised $13.5M funding round, Sep 2011
About
Motus GI is a medical technology company dedicated to improving endoscopy outcomes and experiences. The company is currently focused on bringing to market the Pure-Vu System, which is designed to improve the colonoscopy experience and assist in the early detection and prevention of colorectal cancer and other diseases of the rectum and colon. The Pure-Vu System has the potential to improve the colonoscopy experience for physicians, patients, and payers by diminishing the dependence on preprocedural preparations, thereby enhancing the quality and cost effectiveness of the exam. The Pure-Vu System is a 510(k) U.S. FDA-cleared medical device indicated for cleaning a poorly prepped colon during the colonoscopy procedure, thus decreasing the dependence on preprocedural prep regimens to achieve a thorough colonoscopy. The device fits over most standard colonoscopes, allowing the physician to clean poorly prepped colons in a safe and effective manner to gain clear visualization of the colon mucosa. The Pure-Vu System has received CE mark approval in Europe and FDA clearance to market Pure-Vu Slim Sleeve, a compatible extension to the Pure-Vu System for slim colonoscopies. In 2020, the company received AMAR approval in Israel and CE mark approval for its Gen2 Pure-Vu System.
Funding history · 4 rounds · $64.5M total
Q&A
- What is Motus GI's primary product?
- Motus GI's primary product is the Pure-Vu System, a medical device designed to improve colonoscopy outcomes by cleaning poorly prepped colons during the procedure.
- When was Motus GI founded?
- Motus GI was founded in October 2008.
- What is the current status of Motus GI?
- Motus GI is an active company, publicly traded on NASDAQ since February 2018.
- What was Motus GI's most recent funding round?
- Motus GI completed a funding round in May 2023, raising $3,500,000.
- Which investors participated in Motus GI's February 2017 funding round?
- In February 2017, investors including Ascent Biomedical Ventures.
- What regulatory approvals has the Pure-Vu System received?
- The Pure-Vu System has received 510(k) U.S. FDA clearance, CE mark approval in Europe, and AMAR approval in Israel for its Gen2 Pure-Vu System in 2020.
- Where is Motus GI's headquarters located?
- Motus GI's headquarters is located in Tirat Carmel, Israel.
Sectors & technology
Highlights
Tags
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)
External links
| Website | motusgi.com |
|---|---|
| linkedin.com/company/10597881 | |
| facebook.com/MotusGI | |
| YouTube | youtube.com/channel/UCxoy2H9FLs2FfNQljgR8rHA |
Identifiers & details
| Former names | Booton |
|---|---|
| Founded | 2008-10 |
| Employees (exact) | 23 |
| Offices | Fort Lauderdale |
| Market cap | $639 |
| Status reason | Public on NASDAQ on Feb, 2018 |
Radar intelligence
Patents
| EPO | 16 |
|---|
Web history (Wayback)
| Domain | motusgi.com |
|---|
Certificate / subdomain footprint
| Subdomains | 6 |
|---|